Da li je faktor rasta fibroblasta u serumu 21 povezan sa težinom ili prisustvom bolesti koronarnih arterija?
FGF-21 i bolest koronarnih arterija
Sažetak
Cilj: Nedavna ispitivanja pokazala su da su povećane koncentracije cirkulirajućeg faktora rasta fibroblasta 21 (FGF21) povezane s pretilošću, metaboličkim poremećajem i aterosklerozom. Međutim, studije koje istražuju vezu između nivoa FGF21 u serumu i bolesti koronarnih arterija (CAD) uključuju oprečne podatke. U ovoj studiji planirali smo istražiti ulogu FGF21 u razvoju CAD-a i težini CAD-a.
Metoda: U istraživanje je bilo uključeno sedamdeset osam pacijenata sa stabilnom anginom pektoris (SA) (pozitivna lezija) i 40 kontrolnih bolesnika (lezija negativna) sa sličnim faktorima kardiovaskularnog rizika koji su podvrgnuti koronarnoj angiografiji. Nivoi serumskog FGF21 izmjereni su ELISA metodom. Ozbiljnost CAD-a procijenjena je korištenjem SYNTAX-ovih i GENSINI-ovih rezultata rizika.
Rezultati: Iako je postojala statistički značajna razlika između nivoa FGF21 u serumu u SA i kontrolnim grupama [101,18 ± 141,62 naspram 47,93 ± 58,74 pg / ml; p = 0,03], nije pronađena korelacija između rezultata SINTAKSE (r = 0,146 i p = 0,134) i GENSINI (r = 0,211 i p = 0,084) sa nivoima FGF21 u serumu. SA grupa imala je niže razine HDL-C u serumu (41,57 ± 11,40 naspram 54,90 ± 34,47; p = 0,02). U korelacijskoj analizi postojala je značajna i negativna veza između serumskog FGF21 i nivoa HDL-C u serumu (r = - 0,272; p = 0,026).
Zaključak: Razine serumskog FGF21 razlikuju se između dijagnosticiranih SA i kontrolnih pacijenata. FGF21 može biti marker za dijagnozu CAD-a, ali ne i za procjenu ozbiljnosti CAD-a. Koliko nam je poznato, ovo je prva studija koja je procijenila težinu bolesti koronarnih arterija zajedno s lipidnim profilom.
Reference
2) Domouzoglou EM, Naka KK, Vlahos AP, et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 2015;309:1029-1038. https://pubmed.ncbi.nlm.nih.gov/26232236/
3) Jing C, X Su, Lei Q, et al. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Bioscience Reports (2018) 38 BSR20181099 https://pubmed.ncbi.nlm.nih.gov/30185439/
4) Boesen ME, Singh D, Menon BK, et al. A systematic literature review of the effect of carotid atherosclerosis on local vessel stiffness and elasticity. Atherosclerosis 2015;243:211-222. https://pubmed.ncbi.nlm.nih.gov/26402140/
5) Kousios A, Kouis P, Panayiotou AG. Matrix metalloproteinases and subclinical atherosclerosis in chronic kidney disease: A systematic review. Int J Nephrol 2016; 2016: 9498013, doi: 10.1155/2016/9498013. https://pubmed.ncbi.nlm.nih.gov/27042350/
6) Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic andregulatory pathways. Physiol Rev 2006;86:515-581. https://pubmed.ncbi.nlm.nih.gov/16601268/
7) Weber C, Zernecke A, Libby P. The multifaceted contributionsof leukocyte subsets to atherosclerosis: lessons from mousemodels. Nat Rev Immunol 2008;8:802-815. https://pubmed.ncbi.nlm.nih.gov/18825131/
8) Crickx E, Saussine A, Vignon-Pennamen MD, et al. Diffuse dermal angiomatosis associated with severe atherosclerosis: Two cases and review of the literature. Clin Exp Dermatol 2015;40:521-524. https://pubmed.ncbi.nlm.nih.gov/25639294/
9) Itoh N, Ornitz DM. Evolution of the FGF and FGFr gene families. Trends Genet 2004; 20: 563-569. https://pubmed.ncbi.nlm.nih.gov/15475116/
10) Presta M, Dell’Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178. https://pubmed.ncbi.nlm.nih.gov/15863032/
11) Shen Y, Ma X, Zhou J, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013;12:124. doi: 10.1186/1475-2840-12-124. https://pubmed.ncbi.nlm.nih.gov/23981342/
12) Li H, Zhang J, Jia W. Fibroblast growth factor 21: A novel metabolic regulator from pharmacology to physiology. Front Med. 2013;7:25–30. https://pubmed.ncbi.nlm.nih.gov/23358894/
13) Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635. https://pubmed.ncbi.nlm.nih.gov/15902306/
14) Semba RD, Sun K, Egan JM, et al. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012; 97:1375–1382. https://pubmed.ncbi.nlm.nih.gov/22344195/
15) Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018–6027. https://pubmed.ncbi.nlm.nih.gov/18687777/
16) Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36(1):145-149. https://pubmed.ncbi.nlm.nih.gov/22933429/
17) Khalaf MM, Fayez S, Azou T. Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity.British Journal of Medicine & Medical Research 2016; 18(9): 1-11. https://pubmed.ncbi.nlm.nih.gov/26232236/
18) Kokkinos J, Tang S, Rye KA, et al. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis 2017;257:259-265. https://pubmed.ncbi.nlm.nih.gov/28012645/
19) Lin Z, Pan X, Wu F et al. Fibroblast growth factor 21 prevents atherosclerosis by supression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015;131:1861-1871. https://pubmed.ncbi.nlm.nih.gov/25794851/
20) Monsour HP, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease-its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2013; 8:21–25. https://pubmed.ncbi.nlm.nih.gov/23227282/
21) American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:13-28. https://pubmed.ncbi.nlm.nih.gov/30559228/
22) Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–2219 https://pubmed.ncbi.nlm.nih.gov/23771844/
23) Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23:1–87. https://pubmed.ncbi.nlm.nih.gov/28437620/
24) SYNTAX working group. SYNTAX score calculator. Available at http://www.syntaxscore.com. Accessed May 20, 2012
25) Gensini GG. Coronary arteriography: role in myocardial revascularization. Postgrad Med 1978;63(1):121- 128. https://pubmed.ncbi.nlm.nih.gov/637926/
26) Qing L, Yuan Z, Ding D, et al. Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease. J Clin Endocrinol Metab, 2016; 101(12):4886–4894. https://pubmed.ncbi.nlm.nih.gov/27662438/
27) Stein S, Stepan H, Kratzsch J, et al. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010;59:33–37. https://pubmed.ncbi.nlm.nih.gov/19699495/
28) Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Scientific Reports. 2013;3: 2767. https://doi.org/10.1038/ srep02767. https://pubmed.ncbi.nlm.nih.gov/24067542/
29) Liu SQ, Tefft BJ, Roberts DT, et al. Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(12):1446–1458. https://pubmed.ncbi.nlm.nih.gov/23064833/
30) An SY, Lee MS, Yi SA, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96: 196-203. https://pubmed.ncbi.nlm.nih.gov/22293928/
31) Haifeng C, Nan L, Meifan Z, et al. A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. Am J Transl Res 2018;10(9):2958-2966. https://pubmed.ncbi.nlm.nih.gov/30323882/
32) Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clinical Endocrinology 2014; 80:57–64. https://pubmed.ncbi.nlm.nih.gov/23278761/
33) Matej Stancík. Fibroblast growth factor 21 in prediction of coronary angiography result in stable coronary artery disease patients. Biomed Res DOI: 10.4066/biomedicalresearch-C7-020. https://www.biomedres.info/proceedings/fibroblast-growth-factor-21-in-prediction-of-coronary-angiography-result-in-stable-coronary-artery-disease-patients-2889.html
34) Wang JS, Sheu, WH, Lee, WJ et al. Associations of fibroblast growth factor 21 with cardiovascular risk and β-cell function in patients who had no history of diabetes. Clin. Chim. Acta 2017;(472) 80–85. https://pubmed.ncbi.nlm.nih.gov/28735064/
35) Ling WT, Tian J, Ling HS et al. Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can. J. Physiol. Pharmacol. 2013; (91):973–984. https://pubmed.ncbi.nlm.nih.gov/24117266/
36) Miyazaki Y, Saita E, Kishimoto Y, et al. Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease.Journal of atherosclerosis and thrombosis. 2018;(25):9:821-828. https://pubmed.ncbi.nlm.nih.gov/29367522/
37) Park SD, Bae KH , Choi YK et al. Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease. J Lipid Atheroscler. 2018 ;7(1):42-49. https://e-jla.org/DOIx.php?id=10.12997/jla.2018.7.1.42
38) Kim WJ, Kim SS, Lee HC, et al. Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes. J Korean Med Sci 2015;30:586-590. https://pubmed.ncbi.nlm.nih.gov/25931789/
39) Matuszek B, Lenart-Lipińska M, Duma D, et al. Evaluation of concentrations of FGF21 a new adipocytokine in type 2 diabetes. Polish Journal of Endocrinology 2010;61:50-54. https://pubmed.ncbi.nlm.nih.gov/20205104/
40) Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 2008; 116: 65-68. https://pubmed.ncbi.nlm.nih.gov/17926232/
Sva prava zadržana (c) 2021 Gokay Nar, Sara Cetin Sanlialp, rukiye nar, Oguz Kilic, Mehmet Furkan Ozen, Guven Gunver, Cihan Ilyas Sevgican
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.